IP Library › Granted Patent US 12679904
Granted Patent B2
US 12679904 · App. 18/765,553 · Granted Jul 14, 2026

Cancer vaccines targeting Survivin and uses thereof

Inventors: Jian Yan (Wallingford, PA); Anna Slager (Lansdale, PA); Bradley Garman (Glenside, PA); Neil Cooch (Oreland, PA)
Assignee: Inovio Pharmaceuticals, Inc.
C07K16/40A61K39/00115A61K39/39A61P35/00C12N15/52C12N15/62A61K2039/53A61K2039/55527A61K2039/575
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12679904
App. No.
18/765,553
Granted
Jul 14, 2026
Kind
B2
Abstract

Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens are disclosed. Methods of treating a subject with a Survivin-expressing tumor and methods of preventing a Survivin-expressing tumor are disclosed. Synthetic consensus Survivin antigens are disclosed.

Claims (33)

1 . A nucleic acid molecule comprising one or more nucleic acid sequences selected from the group consisting of:

(a) SEQ ID NO: 9;

(b) SEQ ID NO: 10;

(c) a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 9 encoding SEQ ID NO: 11, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 33, 47, and 83 of SEQ ID NO: 11; and

(d) a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 10 encoding SEQ ID NO: 13, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 33, 47, and 83 of SEQ ID NO: 13.

2 . A nucleic acid molecule comprising one or more nucleic acid sequences selected from the group consisting of:

(a) SEQ ID NO: 1;

(b) SEQ ID NO: 3;

(c) a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 1 encoding SEQ ID NO: 2, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 51, 65, and 101 of SEQ ID NO: 2; and;

(d) a nucleic acid sequence that is at least 95% identical to SEQ ID NO:3 encoding SEQ ID NO: 8, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 51, 65, and 101 of SEQ ID NO: 8.

3 . A nucleic acid molecule comprising the nucleic acid sequence set forth in SEQ ID NO: 1.

4 . A nucleic acid molecule comprising the nucleic acid sequence set forth in SEQ ID NO:3.

5 . A vector comprising a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

(a) SEQ ID NO: 9;

(b) SEQ ID NO: 10;

(c) a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 9 encoding SEQ ID NO: 11; wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 33, 47, and 83 of SEQ ID NO: 11;

(d) a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 10 encoding SEQ ID NO: 13, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 33, 47, and 83 of SEQ ID NO: 13;

(e) SEQ ID NO:1;

(f) SEQ ID NO:3;

(g) a nucleic acid sequence that is at least 95% identical to SEQ ID NO:1 encoding SEQ ID NO: 2, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 51, 65, and 101 of SEQ ID NO: 2; and;

(h) a nucleic acid sequence that is at least 95% identical to SEQ ID NO:3 encoding SEQ ID NO: 8, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 51, 65, and 101 of SEQ ID NO: 8.

6 . The vector of claim 5 , comprising a plasmid or a viral vector.

7 . A composition comprising one or more nucleic acid molecules comprising a nucleic acid sequence selected from the group consisting of:

(a) SEQ ID NO:9;

(b) SEQ ID NO:10;

(c) a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 9 encoding SEQ ID NO: 11, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 33, 47, and 83 of SEQ ID NO: 11;

(d) a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 10 encoding SEQ ID NO: 13, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 33, 47, and 83 of SEQ ID NO: 13;

(e) SEQ ID NO:1;

(f) SEQ ID NO:3;

(g) a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 1 encoding SEQ ID NO: 2, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 51, 65, and 101 of SEQ ID NO: 2; and

(h) a nucleic acid sequence that is at least 95% identical to SEQ ID NO:3 encoding SEQ ID NO: 8, wherein the nucleic acid sequence encodes a protein comprising SEQ ID NO: 5 and an alanine at positions 51, 65, and 101 of SEQ ID NO: 8.

8 . The composition of claim 7 comprising a pharmaceutically acceptable carrier.

9 . A composition comprising one or more vectors as set forth in claim 5 .